KBRA Europe Releases Research ? Demand for Environmentally Friendly European Power Assets Risks Weakening Credit Profiles
Kroll Bond Rating Agency Europe Limited (KBRA) releases research on developments in renewable project finance. KBRA has observed several trends that place a spotlight on merchant risk in European renewable project finance. Incentives provided for environmental, social, and governance (ESG) projects have encouraged the development of a competitive market by subsidising pricing as well as driving developments in the funding markets. KBRA has observed an increase in the number of project finance transactions more directly exposed to the power markets and risks weakening credit profiles without effective structural support.
Key Takeaways
Factors that influence the quality of projects (supply) and their exposure to power market risk include: (i) the phasing out of renewable energy subsidies by European governments, (ii) lower pricing support provided by contracts for difference (CfDs) as auction prices decrease, and (iii) a rise in the number of renewable energy projects.
Factors influencing the demand for project finance transactions, which in turn further increase the exposure to power markets, include: (i) investors increasingly chasing ESG-focused assets with renewable energy style funding, (ii) supplier demand for renewable energy projects to meet demands from clients, and (iii) financial innovation to meet the need for higher yields from investors.
These factors have created an environment that is increasingly exposed to power price volatility, refinancing risk, and liquidity risk. This raises questions around renewable project financing credit risk and how it is mitigated. In this report, we outline the various factors at play and how funding methods are adapting to these risks.
KBRA is a full-service credit rating agency registered in the U.S., the EU and the UK, and is designated to provide structured finance ratings in Canada. KBRA's ratings can be used by investors for regulatory capital purposes in multiple jurisdictions.
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...
Banco Latinoamericano de Comercio Exterior, S.A. , a Panama-based multinational bank originally established by the central banks of 23 Latin-American and Caribbean countries to promote foreign trade and economic integration in the Region, announced...